文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高剂量率与低剂量率近距离放疗推量对前列腺癌外照射后毒性及疗效的影响:基于全国人群的研究

Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-03

该观察性队列研究利用英格兰国家癌症登记等关联数据,纳入54,642例中危、高危和局部晚期前列腺癌患者,比较外照射(EBRT)联合高剂量率(HDR-BB)或低剂量率(LDR-BB)近距离放疗推量及单纯EBRT的5年毒性与肿瘤结局。结果显示LDR-BB胃肠道与泌尿生殖毒性均升高,HDR-BB泌尿生殖毒性升高,但HDR-BB的骨相关事件和前列腺癌特异性死亡率低于单纯EBRT。

要点

  • LDR-BB的5年胃肠道毒性(32.3%)高于HDR-BB(16.7%)和单纯EBRT(18.7%)。
  • LDR-BB与HDR-BB的5年泌尿生殖毒性均高于单纯EBRT(15.8%、16.6% vs 10.4%)。
  • HDR-BB的5年骨相关事件和前列腺癌特异性死亡率低于单纯EBRT。

核心结论

  • 与单纯EBRT相比,LDR-BB的胃肠道和泌尿生殖毒性更差,HDR-BB的泌尿生殖毒性更差。
  • HDR-BB的骨相关事件和前列腺癌特异性死亡率低于单纯EBRT。

研究设计与样本

  • 观察性队列研究,使用英格兰关联的国家癌症登记、放疗、行政住院和死亡记录数据,纳入54,642例中危、高危和局部晚期前列腺癌患者。
  • 其中11,676例记录关联了诊断后至少18个月收集的全国患者调查结果,采用竞争风险回归和线性回归分析。

主要发现

  • 5年胃肠道毒性:LDR-BB为32.3%,HDR-BB为16.7%,单纯EBRT为18.7%。
  • 5年泌尿生殖毒性:LDR-BB为15.8%,HDR-BB为16.6%,单纯EBRT为10.4%。
  • 患者报告肠道功能平均分:LDR-BB为77.3,HDR-BB为85.8,单纯EBRT为84.4。
  • 患者报告泌尿梗阻/刺激功能平均分:LDR-BB为72.2,HDR-BB为78.9,单纯EBRT为83.8。
  • 5年骨相关事件与前列腺癌特异性死亡率:HDR-BB分别为2.4%和2.7%,单纯EBRT分别为2.8%和3.5%。

关键数值与推荐

  • 患者报告功能评分采用EPIC-26量表(0-100分,分数越高功能越好)。
  • 毒性、骨相关事件和前列腺癌特异性死亡率均为5年结局,并校正患者和肿瘤特征。

临床怎么用

  • 对接受EBRT的前列腺癌患者选择近距离放疗推量方式时,需权衡LDR-BB较高的胃肠道与泌尿生殖毒性和HDR-BB较高的泌尿生殖毒性。
  • HDR-BB在骨相关事件和前列腺癌特异性死亡率方面显示优于单纯EBRT,可作为推量决策的参考。

局限性

  • 为观察性队列研究,非随机对照试验,无法排除混杂。
  • 患者报告结局仅来自11,676例关联调查数据的子集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: External beam radiation therapy (EBRT) with brachytherapy boost reduces cancer recurrence in patients with prostate cancer compared with EBRT monotherapy. However, randomized controlled trials or large-scale observational studies have not compared brachytherapy boost types directly. METHODS AND MATERIALS: This observational cohort study used linked national cancer registry data, radiation therapy data, administrative hospital data, and mortality records of 54,642 patients with intermediate-risk, high-risk, and locally advanced prostate cancer in England. The records of 11,676 patients were also linked to results from a national patient survey collected at least 18 months after diagnosis. Competing risk regression analyses were used to compare gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, skeletal-related events (SRE), and prostate cancer-specific mortality (PCSM) at 5 years with adjustment for patient and tumor characteristics. Linear regression was used to compare Expanded Prostate Cancer Index Composite 26-item version domain scores (scale, 0-100, with higher scores indicating better function). RESULTS: Five-year GI toxicity was significantly increased after low-dose-rate brachytherapy boost (LDR-BB) (32.3%) compared with high-dose-rate brachytherapy boost (HDR-BB) (16.7%) or EBRT monotherapy (18.7%). Five-year GU toxicity was significantly increased after both LDR-BB (15.8%) and HDR-BB (16.6%), compared with EBRT monotherapy (10.4%). These toxicity patterns were matched by the mean patient-reported bowel function scores (LDR-BB, 77.3; HDR-BB, 85.8; EBRT monotherapy, 84.4) and the mean patient-reported urinary obstruction/irritation function scores (LDR-BB, 72.2; HDR-BB, 78.9; EBRT monotherapy, 83.8). Five-year incidences of SREs and PCSM were significantly lower after HDR-BB (2.4% and 2.7%, respectively) compared with EBRT monotherapy (2.8% and 3.5%, respectively). CONCLUSIONS: Compared with EBRT monotherapy, LDR-BB has worse GI and GU toxicity and HDR-BB has worse GU toxicity. HDR-BB has a lower incidence of SREs and PCSM than EBRT monotherapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Parry MG, Nossiter J, Sujenthiran A, et al. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 33279595. doi:10.1016/j.ijrobp.2020.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。